95 related articles for article (PubMed ID: 30289427)
1. Bcl-3 promotes proliferation and chemosensitivity in BL1 subtype of TNBC cells.
Huo J; Chen X; Zhang H; Hu Y; Jiang Y; Liu S; Zhang X
Acta Biochim Biophys Sin (Shanghai); 2018 Nov; 50(11):1141-1149. PubMed ID: 30289427
[TBL] [Abstract][Full Text] [Related]
2. MET is a potential target for use in combination therapy with EGFR inhibition in triple-negative/basal-like breast cancer.
Kim YJ; Choi JS; Seo J; Song JY; Lee SE; Kwon MJ; Kwon MJ; Kundu J; Jung K; Oh E; Shin YK; Choi YL
Int J Cancer; 2014 May; 134(10):2424-36. PubMed ID: 24615768
[TBL] [Abstract][Full Text] [Related]
3. Combination Treatment of Polo-Like Kinase 1 and Tankyrase-1 Inhibitors Enhances Anticancer Effect in Triple-negative Breast Cancer Cells.
Ha GH; Kim DY; Breuer EK; Kim CK
Anticancer Res; 2018 Mar; 38(3):1303-1310. PubMed ID: 29491053
[TBL] [Abstract][Full Text] [Related]
4. Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer.
Cheng G; Fan X; Hao M; Wang J; Zhou X; Sun X
Mol Cancer; 2016 Apr; 15(1):30. PubMed ID: 27130446
[TBL] [Abstract][Full Text] [Related]
5. Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.
Torres-Adorno AM; Lee J; Kogawa T; Ordentlich P; Tripathy D; Lim B; Ueno NT
Clin Cancer Res; 2017 Aug; 23(16):4780-4792. PubMed ID: 28465444
[No Abstract] [Full Text] [Related]
6. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.
Vázquez R; Riveiro ME; Astorgues-Xerri L; Odore E; Rezai K; Erba E; Panini N; Rinaldi A; Kwee I; Beltrame L; Bekradda M; Cvitkovic E; Bertoni F; Frapolli R; D'Incalci M
Oncotarget; 2017 Jan; 8(5):7598-7613. PubMed ID: 27935867
[TBL] [Abstract][Full Text] [Related]
7. A comparison of the molecular subtypes of triple-negative breast cancer among non-Asian and Taiwanese women.
Tseng LM; Chiu JH; Liu CY; Tsai YF; Wang YL; Yang CW; Shyr YM
Breast Cancer Res Treat; 2017 Jun; 163(2):241-254. PubMed ID: 28299476
[TBL] [Abstract][Full Text] [Related]
8. Combination of the novel histone deacetylase inhibitor YCW1 and radiation induces autophagic cell death through the downregulation of BNIP3 in triple-negative breast cancer cells in vitro and in an orthotopic mouse model.
Chiu HW; Yeh YL; Wang YC; Huang WJ; Ho SY; Lin P; Wang YJ
Mol Cancer; 2016 Jun; 15(1):46. PubMed ID: 27286975
[TBL] [Abstract][Full Text] [Related]
9. Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection.
Lehmann BD; Jovanović B; Chen X; Estrada MV; Johnson KN; Shyr Y; Moses HL; Sanders ME; Pietenpol JA
PLoS One; 2016; 11(6):e0157368. PubMed ID: 27310713
[TBL] [Abstract][Full Text] [Related]
10. High expression of FUSE binding protein 1 in breast cancer stimulates cell proliferation and diminishes drug sensitivity.
Liu W; Xiong X; Chen W; Li X; Hua X; Liu Z; Zhang Z
Int J Oncol; 2020 Aug; 57(2):488-499. PubMed ID: 32626933
[TBL] [Abstract][Full Text] [Related]
11. Dual inhibition of EGFR and MET induces synthetic lethality in triple-negative breast cancer cells through downregulation of ribosomal protein S6.
Yi YW; You K; Bae EJ; Kwak SJ; Seong YS; Bae I
Int J Oncol; 2015 Jul; 47(1):122-32. PubMed ID: 25955731
[TBL] [Abstract][Full Text] [Related]
12. miR-17-5p suppresses cell proliferation and invasion by targeting ETV1 in triple-negative breast cancer.
Li J; Lai Y; Ma J; Liu Y; Bi J; Zhang L; Chen L; Yao C; Lv W; Chang G; Wang S; Ouyang M; Wang W
BMC Cancer; 2017 Nov; 17(1):745. PubMed ID: 29126392
[TBL] [Abstract][Full Text] [Related]
13. Loss of RAB1B promotes triple-negative breast cancer metastasis by activating TGF-β/SMAD signaling.
Jiang HL; Sun HF; Gao SP; Li LD; Hu X; Wu J; Jin W
Oncotarget; 2015 Jun; 6(18):16352-65. PubMed ID: 25970785
[TBL] [Abstract][Full Text] [Related]
14. WBP2 Downregulation Inhibits Proliferation by Blocking YAP Transcription and the EGFR/PI3K/Akt Signaling Pathway in Triple Negative Breast Cancer.
Song H; Wu T; Xie D; Li D; Hua K; Hu J; Fang L
Cell Physiol Biochem; 2018; 48(5):1968-1982. PubMed ID: 30092563
[TBL] [Abstract][Full Text] [Related]
15. Filamin A (FLNA) modulates chemosensitivity to docetaxel in triple-negative breast cancer through the MAPK/ERK pathway.
Zhao P; Ma W; Hu Z; Zang L; Tian Z; Zhang K
Tumour Biol; 2016 Apr; 37(4):5107-15. PubMed ID: 26546439
[TBL] [Abstract][Full Text] [Related]
16. Sulforaphene inhibits triple negative breast cancer through activating tumor suppressor Egr1.
Yang M; Teng W; Qu Y; Wang H; Yuan Q
Breast Cancer Res Treat; 2016 Jul; 158(2):277-86. PubMed ID: 27377973
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-455-3p promotes invasion and migration in triple negative breast cancer by targeting tumor suppressor EI24.
Li Z; Meng Q; Pan A; Wu X; Cui J; Wang Y; Li L
Oncotarget; 2017 Mar; 8(12):19455-19466. PubMed ID: 28038450
[TBL] [Abstract][Full Text] [Related]
18. Synergistic antitumor effect of NVP-BEZ235 and CAPE on MDA-MB-231 breast cancer cells.
Torki S; Soltani A; Shirzad H; Esmaeil N; Ghatrehsamani M
Biomed Pharmacother; 2017 Aug; 92():39-45. PubMed ID: 28528184
[TBL] [Abstract][Full Text] [Related]
19. FOXM1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorgenesis of human triple negative breast cancer cells.
Hamurcu Z; Ashour A; Kahraman N; Ozpolat B
Oncotarget; 2016 Mar; 7(13):16619-35. PubMed ID: 26918606
[TBL] [Abstract][Full Text] [Related]
20. hMAGEA2 promotes progression of breast cancer by regulating Akt and Erk1/2 pathways.
Park S; Sung Y; Jeong J; Choi M; Lee J; Kwon W; Jang S; Park SJ; Kim HS; Lee MH; Kim DJ; Liu K; Kim SH; Dong Z; Ryoo ZY; Kim MO
Oncotarget; 2017 Jun; 8(23):37115-37127. PubMed ID: 28415749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]